Additionally, Chinese multicenter retrospective studies (CHANCE001 and CHANCE2201) suggested that triple therapy (TACE combined with PD-(L)1 inhibitors plus molecular targeted therapies) provided longer overall survival than TACE alone or PD-(L)1 inhibitors plus molecular targeted therapies in unresectable HCC (14, 15). The gene discussed is CD274; the disease is hepatocellular carcinoma.